# GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)

Clinical trial · Samsung Pharmaceutical Co., Ltd.

- Archive id: nct:NCT05303701
- Published: 2022-03-31
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05303701
- Source URL: https://clinicaltrials.gov/study/NCT05303701
- Provenance: clinicaltrials

## Abstract

The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: NOT_YET_RECRUITING
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 750
- sponsor: Samsung Pharmaceutical Co., Ltd.
- conditions: Moderate to Severe Alzheimer's Disease
- interventions: DRUG: GV1001 Placebo; DRUG: GV1001 1.12mg
- start date: 2027-07-01
- start date type: ESTIMATED
- primary completion date: 2028-01-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Alzheimer's, Parkinson's & Neurodegeneration](https://space-kitty.com/topics/neurodegeneration)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.